Details of the Drug Reposition

General Information of This Drug (ID: DM75RFJ)

Drug Name
Siplizumab   DM75RFJ
Synonyms Siplizumab (USAN/INN)
Drug Type
Antibody

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
1 Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Lymphoma DISN6V4S 2A80-2A86 Phase 2 [1]
------------------------------------------------------------------------------------
1 Discontinued in Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Psoriasis vulgaris DIS6M7AN EA90 Discontinued in Phase 2 [2]
------------------------------------------------------------------------------------

References

1 Safety profile of intravenous and subcutaneous siplizumab, an anti-CD2 monoclonal antibody, for the treatment of plaque psoriasis: results of two randomized, double-blind, placebo-controlled studies.Int J Dermatol. 2010 Jul;49(7):818-28.
2 Emerging drugs for moderate-to-severe psoriasis. Expert Opin Emerg Drugs. 2005 Feb;10(1):35-52.